Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival

Clinical Cancer Research

Volumn 14, Issue 18, 2008, Pages 5884-5892

  Van Cruijsen, Hester ^a   Van Der Veldt, Astrid A M ^a   Vroling, Laura ^a   Oosterhoff, Dinja ^a   Broxterman, Henk J ^a   Scheper, Rik J ^a   Giaccone, Giuseppe ^a,c   Haanen, John B A G ^b   Van Den Eertwegh, Alfons J M ^a   Boven, Epie ^a   Hoekman, Klaas ^a   De Gruijl, Tanja D ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; CD1C ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 6; STEM CELL FACTOR RECEPTOR; SUNITINIB; VASCULOTROPIN RECEPTOR; CD1 ANTIGEN; CD1C PROTEIN, HUMAN; GLYCOPROTEIN; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CANCER PATIENT; CANCER REGRESSION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELLULAR DISTRIBUTION; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN CELL; KIDNEY CANCER; LEUKOPENIA; MALE; MONOCYTE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR REGRESSION; DISEASE FREE SURVIVAL; IMMUNOLOGY; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD1; CARCINOMA, RENAL CELL; CELL LINEAGE; DENDRITIC CELLS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MYELOID CELLS; PYRROLES;

EID: 53249111806     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0656     Document Type: Article

References (42)

1. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004;4:941-52.
2. Delia BS, Gennaro M, Vaccari M, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer 2003;89:1463-72.
3. Van Cruijsen H, Hoekman K, Stam AGM, et al. Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor. Clin Dev Immunol 2007;8:17315. Epub 2008 Jan 10.
4. Almand B, Resser JR. Lindman B, et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
5. Gabrilovich Dl, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.
6. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150-66.
7. Gabrilovich Dl, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996;2:1096-103.
8. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich Dl. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260-8.
9. Boissel N, Rousselot P, Raffoux E, et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004;18:1656-61.
10. Saito H, Tsujitani S, Ikeguchi M, Maeta M, Kaibara N. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573-7.
11. Inoshima N, Nakanishi Y, Minami T, et al. The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res 2002;8:3480-6.
12. Fricke I, Mirza N, Dupont J, et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res 2007;13:4840-8.
13. Osada T, Chong G, Tansik R, et al. The effect of anti- VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother 2008;57:1115-24. Epub 2008 Jan 10.
14. Valenti R, Huber V, Filipazzi P, et al. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor- β-mediated suppressive activity on T lymphocytes. Cancer Res 2006;66:9290-8.
15. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
16. Motzer RJ, Rini Bl, Bukowski RM, et al. Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JAMA 2006;295:2516-24.
17. Motzer RJ, HutsonTE, Tomczak P, et al. Sunitinib versus interteron alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
18. Curti A, Fogli M, Ratta M, Tura S, Lemoli RM. Stem cell factor and FLT3-ligand are strictly required to sustain the long-term expansion of primitive CD34+DR- dendritic cell precursors. J Immunol 2001;166:848-54.
19. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007;356:185-7.
20. Baldewijns MM, Thijssen VL, Van den Eynden GG, et al. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile. Br J Cancer 2007;96:1888-95.
21. Schips L, Dalpiaz O, Lipsky K, et al. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. Eur Urol 2007;51:168-74.
22. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-30.
23. Donskov F, der Maase H. Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol 2006;24:1997-2005.
24. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007;110:543-50.
25. Rissoan MC, Soumelis V, Kadowaki N, et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-6.
26. MacDonald KP, Munster DJ. Clark GJ, Dzionek A, Schmitz J, Hart DN. Characterization of human Wood dendritic cell subsets. Blood 2002;100:4512-20.
27. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006;24:25-35.
28. Almand B. Clark Jl, Nikrtina E. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
29. Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000;165:6037-46.
30. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002;20: 289-96.
31. Demetri GD, van Oosterom AT. Garrett CR. et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006; 368:1329-38.
32. Deprimo SE, Bello CL. Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
33. Schmielau J, Finn OJ. Activated granulocytes and granulocyte-derived hydrogen peroxide are the underlying mechanism of suppression of T-cell function in advanced cancer patients. Cancer Res 2001;61: 4756-60.
34. Munder M, Schneider H, Luckner C, et al. Suppression of T-cell functions by human granulocyte arginase. Blood 2006;108:1627-34.
35. Kono K, Salazar-Onfray F, Petersson M, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing ζ molecules and inhibits tumor-specificTcell-and natural killer cell-mediated cytotoxicity. Eur J Immunol 1996; 26:1308-13.
36. Hansson M, Asea A, Ersson U, Hermodsson S. Hellstrand K. Induction of apoptosis in NK cells by monocyte-derived reactive oxygen metabolites. J Immunol 1996;156:42-7.
37. AbramsTJ, Lee LB, Murray LJ, et al. SU11248 inhibits KITand platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol CancerTher 2003;2:471-8.
38. O'Farrell AM, Abrams TJ, Yuen HA. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101:3597-605.
39. Menetrier-Caux C, Montmain G, Dieu MC, et al. Inhibition of the differentiation of dendritic cells from CD34+ progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998;92:4778-91.
40. Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab 2006;91:4070-6.
41. Ripperger J, Fritz S, Richter K. et al. Isolation of two interleukin-6 response element binding proteins from acute phase rat livers. Ann N Y Acad Sci 1995;762: 252-60.
42. Bharadwaj U, Li M, Zhang R, Chen C, Yao Q. Elevated interleukin-6 and G-CSF in human pancreatic cancer cell conditioned medium suppress dendritic cell differentiation and activation. Cancer Res 2007;67: 5479-88.